Background: A subanalysis study of the ENGAGE AF-TIMI 48 trial showed that cardiac troponin I, N-terminal proB-type natriuretic peptide, and D-dimer, were powerful predictors of cerebrovascular adverse events. We aimed to evaluate D-dimer and cardiac troponin I levels during the acute period of ischemic stroke in anticoagulation-naïve patients with nonvalvular atrial fibrillation (NVAF) and also studied the association between these biomarkers and stroke severity.
INTRODUCTION
The most common risk stratification method used to predict embolic events in non-valvular atrial fibrillation (NVAF) is the CHA 2 DS 2 -VASc risk score, which is based on congestive heart failure, hypertension, age, diabetes melli- showed that cardiovascular biomarkers, in particular, cardiac troponin I, N-terminal proB-type natriuretic peptide, and D-dimer, were powerful predictors of cerebrovascular adverse events, and even higher predictors of deaths which were not reflected in CHA 2 DS 2 -VASc risk score. 4 In this study, we evaluated the troponin I and D-dimer levels during the acute stage of ischemic stroke in anticoagulation-naïve patients with NVAF to verify the implications of these biomarkers on cerebrovascular events, as shown in the above-mentioned subanalysis study. The fact that biomarkers are dynamic and change with time suggests the need to evaluate cardiovascular biomarkers just prior to or immediately after embolic events.
We also studied the association between these biomarkers and initial stroke severity. Hypothetically, an increase in biomarkers associated with higher blood stasis and hypercoagulability will predict larger thrombus formation and more severe neurologic deficits. Additionally, if there is a significant association between these biomarkers, they could be useful for predicting not only a simple embolic event, but also stroke severity, which is the most important prognostic factor for long-term functional outcomes. 
METHODS

Patients
Stroke severity assessment
Stroke severity was assessed at the time of admission using the National Institutes of Health Stroke Scale (NIHSS; scores range from 0 to 42, with higher scores indicating greater deficits). 5 Ischemic stroke severity was dichotomized into either mild or moderate-to-severe neurologic deficit using an NIHSS score cutoff of 10 based on previous studies. 6, 7 Biomarker assessment
Blood samples for measuring troponin I and serum Ddimer levels were obtained immediately after admission to the emergency department before any intravenous fluids or medications were administered. Cardiac troponin I was measured (ethylene-diamine-tetraacetic-acid plasma) using a commercially available sensitive assay (TnI-Ultra;
Siemens Healthcare Diagnostics, Erlangen, Germany) with a lower detection limit of 0.006 ng/mL and an established 99th percentile reference limit of 0.04 ng/mL, with a coefficient of variation of 10% at a concentration of 0.03 ng/mL. 
Statistical analyses
Statistical analyses were performed using SPSS for Windows version 17.0 (SPSS Inc., Chicago, IL, USA). Pearson's χ 2 test, an independent sample t -test, and Fisher's exact test were appropriately used. Because D-dimer and troponin I value distributions were markedly right-skewed ( Fig.   1 ), data transformations using a natural logarithm were performed to reduce right skewness, and log-transformed values were used for further analysis. Correlations between the log-transformed values for troponin I/D-dimer and NIHSS score were determined using a partial correlation coefficient adjusted for CHA 2 DS 2 -VASc risk factors.
The log-transformed values for troponin I and D-dimer were divided by quartile (Q1, Q2, Q3, and Q4), and odds ratios were calculated for moderate-to-severe neurological deficits (defined as NIHSS ≥10), using logistic multivariate regression analysis adjusted for CHA 2 DS 2 -VASc risk factors.
The area of the Receiver Operation Characteristic Curve (ROC) and the cutoff value of the serum D-dimer level for the severe neurologic deficit (NIHSS ≥10) were also determined.
RESULTS
Baseline characteristics
A total of 98 consecutive anticoagulation-naïve patients A B 
Distribution of serum D-dimer and troponin I levels
The median values for serum D-dimer levels were 0.94, 0.60, and 2.34 mg/L for all enrolled patients i.e., the mild neurologic deficit group, and the moderate-to-severe neurologic deficit group, respectively, and all these median values were above the upper limit of the normal reference range ( Table 1) . Mean D-dimer levels were significantly The median values for troponin I levels were 0.026, 0.017, and 0.05 pg/mL, respectively, for all study subjects and subgroups i.e., the mild neurologic deficit group, and the moderate-to-severe neurologic deficit group, respectively. Although the median values of troponin I among all enrolled patients and the mild neurologic deficit group were within the normal reference range, this value was above the upper limit for the normal reference range (0.04 mg/L) in the moderate-to-severe neurologic deficit group (Table 1) . 8 Mean troponin I values were not significantly different between the mild and moderate-to-severe neurologic deficit groups. The IQR of troponin I was 0.007-0.100 pg/mL. The distribution of troponin I levels also showed severe right skewness, as seen in Fig. 1B .
Correlation between biomarkers and stroke severity
The partial correlation coefficient analysis adjusted for CHA 2 DS 2 -VASc risk factors showed the log-transformed values of D-dimer were positively correlated with increasing NIHSS score (r=0.233; P =0.051) (Fig. 3A) . The logtransformed values for troponin I did not correlate with the (Fig. 3B ).
Biomarkers as a prognostic risk factor for severe neurologic deficit
When compared to patients with the lowest log-transformed D-dimer (<0.87) after adjustment for CHA 2 DS 2 -VASc risk factors, patients in the upper two quartiles (Q3 and Q4) had higher odds for more severe strokes ( Table 2 ). Odds ratios were 30.1 (95% confidence interval [CI], 1.9-486.2, P=0.017) and 29.7 (95% CI, 2.0-430.8, P=0.013) when the log-transformed D-dimer ranged from -0.06 to 1.00 and ≥1.00, respectively. The area of the ROC for the serum D-dimer was 0.76 (P<0.001) and when the cutoff value of serum D-dimer level for the severe neurologic deficit (NI-HSS ≥10) was determined as 1.64 mg/L, the sensitivity, and the specificity were 70% and 78%, respectively.
Compared with the lowest quartile of the log-transformed troponin I value (-4.96) adjusted for CHA 2 DS 2 -VASc risk factors, only patients in the second upper quartile (Q3) had a significantly higher odds ratio for severe stroke (6.5; 95% CI, 1.3-32.1; P =0.021), when assessing the impact of troponin I levels. The first and third (Q4 and Q1) upper quartiles did not have significant odds of a more severe stroke.
DISCUSSION
In this study, we evaluated dynamically changing cardiovascular biomarkers during the acute period of ischemic A B Use of the D-dimer level as a reflection of the thrombogenic condition and thrombus burden in patients with AF, has been further supported by findings that high serum Ddimer levels in AF were reduced by anticoagulation and cardioversion to sinus rhythm. 11, 12 Our findings in terms of D-dimer are in line with previous studies and the recent subanalysis study of the ENGAGE AF-TIMI 48 trial showing that a higher D-dimer value was associated with increased risk for adverse cerebrovascular events. 4, [13] [14] [15] [16] [17] Several researchers have also reported the cross-sectional association between D-dimer levels and stroke severity in prior studies. [18] [19] [20] However, most of these cross-sectional studies included the patients with ischemic stroke from heterogeneous etiologies and did not focus only on the cardioembolic stroke. In addition, while those studies did not measure the troponin I levels, our study measured troponin I levels, as well as D-dimer levels simultaneously, so that it could provide support for the validity of these biomarkers in predicting adverse embolic events, as shown in the recent subanalysis study of the ENGAGE AF-TIMI 48 trial. 4 The anticoagulation-naïve status of the entire study population was also an advantage over other studies, since anticoagulation reduces biomarker levels, 11 but this also led to a small number of enrolled patients, because anticoagulation-naïve acute ischemic stroke patients with previously diagnosed AF or newly diagnosed AF were less common than expected.
With regard to troponin I, the subanalysis study of the ENGAGE AF-TIMI 48 trial showed a consistently significant association with the incidence of embolic events. 4 However, the cross-sectional values in an acute period of stroke in this study were not higher than the normal upper limit in most patients, and did not show a significant association with stroke severity in contrast to the D-dimer level. For the acute period of the ischemic stroke, D-dimer seemed to be more significantly associated with NVAF-related ischemic stroke compared to troponin I. Perhaps it could be one of the plausible explanations for this discrepancy that D-dimer is the direct byproduct of fibrin, reflecting the thrombus burden itself; therefore, it has more advantages than troponin I in evaluating the relevant aspects of thrombus burden, such as stroke severity, while troponin I is just a cardiac and skeletal muscle protein. We believe that it is reasonable to hypothesize that these biomarkers could be used to predict the future cardiovascular adverse event prospectively.
Cardioembolic infarction is particularly known to be as- showed that, while D-dimer levels were higher in patients with severe stroke after adjusting for confounding factors, this was not statistically significant. 21 Further large studies are necessary to address the exact relationship between Ddimer levels and stroke severity.
CONCLUSION
D-dimer levels were higher in anticoagulation-naïve patients with acute ischemic stroke due to NVAF and an increased D-dimer level was significantly associated with more severe initial neurologic deficits compared to lower D-dimer levels. In contrast, troponin I was not consistently associated with stroke severity.
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